Form 4: Aligos Therapeutics Executive Acquires Stock Options

Lesley Ann Calhoun, Chief Operating Officer and Chief Financial Officer of Aligos Therapeutics, acquired stock options for 47,271 shares on February 28, 2025.

Summary

• Lesley Ann Calhoun, the Chief Operating Officer and Chief Financial Officer of Aligos Therapeutics, acquired stock options on February 28, 2025.
• The options grant the right to buy 47,271 shares of Aligos Therapeutics common stock at an exercise price of $16.87 per share.
• The options vest in 48 equal monthly installments starting from February 28, 2025, and will be fully vested on the fourth anniversary of that date, contingent upon continued service.
• The expiration date for these options is February 28, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a key executive is generally a positive sign, indicating confidence in the company's future. However, it's a routine event and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a key executive signals confidence in the company's future performance.

Future Outlook

The vesting schedule suggests a long-term commitment from the executive to the company's success.

Management Comments

• No direct quotes are available, but the filing was signed by Lesley Ann Calhoun.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Aligos Therapeutics.
• The vesting schedule of 4 years is typical for such grants, aligning executive incentives with long-term company performance.
• Comparable companies such as Gilead Sciences, Vertex Pharmaceuticals, and BioMarin Pharmaceutical also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, incentivizing them to increase shareholder value.

Key Dates